This “Myelofibrosis - Pipeline Insight, 2021” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Myelofibrosis is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. It is considered as a form of chronic leukemia. When myelofibrosis occurs on its own, it is called as primary myelofibrosis. If the disease occur as the result of a separate disease, it is known as secondary myelofibrosis. One characteristic of myelofibrosis is the overproduction of giant cells called megakaryocytes. Risk factors for myelofibrosis include exposure to ionizing radiation or to petrochemicals, such as benzene or toluene. The diagnosis of myelofibrosis include physical examination, blood tests, imaging tests, bone marrow examination, and gene tests to look for gene mutations in blood cells that are associated with myelofibrosis. Myelofibrosis treatment usually depends on the types of symptoms. Jakafi (ruxolitinib) is the first drug approved by the Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis.
"Myelofibrosis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelofibrosis pipeline landscape is provided which includes the disease overview and Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Myelofibrosis.
This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). The drug is in Phase III clinical evaluation in combination with Ruxolitinib for the treatment of myelofibrosis.
KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. The drug is in Phase II clinical studies for the treatment of Myelofibrosis.
This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 45+ key companies which are developing the therapies for Myelofibrosis. The companies which have their Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.
This report covers around 45+ products under different phases of clinical development like
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Myelofibrosis Understanding
Myelofibrosis: Overview
Myelofibrosis is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. It is considered as a form of chronic leukemia. When myelofibrosis occurs on its own, it is called as primary myelofibrosis. If the disease occur as the result of a separate disease, it is known as secondary myelofibrosis. One characteristic of myelofibrosis is the overproduction of giant cells called megakaryocytes. Risk factors for myelofibrosis include exposure to ionizing radiation or to petrochemicals, such as benzene or toluene. The diagnosis of myelofibrosis include physical examination, blood tests, imaging tests, bone marrow examination, and gene tests to look for gene mutations in blood cells that are associated with myelofibrosis. Myelofibrosis treatment usually depends on the types of symptoms. Jakafi (ruxolitinib) is the first drug approved by the Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis.
"Myelofibrosis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelofibrosis pipeline landscape is provided which includes the disease overview and Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Myelofibrosis.
Myelofibrosis Emerging Drugs Chapters
This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myelofibrosis Emerging Drugs
Parsaclisib: Incyte Corporation
Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). The drug is in Phase III clinical evaluation in combination with Ruxolitinib for the treatment of myelofibrosis.
KER-050: Keros Therapeutics
KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. The drug is in Phase II clinical studies for the treatment of Myelofibrosis.
Myelofibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Myelofibrosis
There are approx. 45+ key companies which are developing the therapies for Myelofibrosis. The companies which have their Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.
Phases
This report covers around 45+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myelofibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.
Myelofibrosis Report Insights
- Myelofibrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Myelofibrosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myelofibrosis drugs?
- How many Myelofibrosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelofibrosis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myelofibrosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myelofibrosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Incyte Corporation
- Keros Therapeutics
- Karyopharm Therapeutics
- Celgene Corporation
- PharmaEssentia
- Novartis
- Secura Bio
- Pharmaxis
- Novartis Oncology
- AstraZeneca
- Cellenkos
- Jacobio Pharmaceuticals
- Ohm oncology
Key Products
- Parsaclisib
- KER-050
- Selinexor
- Lenalidomide
- Ropeginterferonum alfa-2b
- Panobinostat
- PXS-5505
- Spartalizumab
- Selumetinib
- CK-0804
- JAB-8263
- OHM-581
Table of Contents
IntroductionExecutive Summary
Myelofibrosis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Myelofibrosis - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Parsaclisib: Incyte Corporation
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
KER-050: Keros Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
PXS-5505: Pharmaxis
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
CK-0804: Cellenkos
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis- Unmet Needs
Myelofibrosis- Market Drivers and Barriers
Myelofibrosis- Future Perspectives and Conclusion
Myelofibrosis Analyst Views
AppendixList of Tables
Table 1 Total Products for Myelofibrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Myelofibrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Incyte Corporation
- Keros Therapeutics
- Karyopharm Therapeutics
- Celgene Corporation
- PharmaEssentia
- Novartis
- Secura Bio
- Pharmaxis
- Novartis Oncology
- AstraZeneca
- Cellenkos
- Jacobio Pharmaceuticals
- Ohm oncology
